Table of contents
- Overview of the Vibostolimab trials
- Cancer types studied
- Trial phases and study designs
- Who could take part
- Main outcomes measured
- Key studies in the data
- What these trials mean for patients
Overview of the Vibostolimab trials
The trial data shows that Vibostolimab was studied in several interventional trials, which means researchers gave a study treatment and then measured the results.[1] Most studies looked at Vibostolimab as part of a combination with other cancer treatments, especially in people with advanced or hard-to-treat cancer.[1]
The studies were done in different settings, including authorised, completed, and withdrawn trials.[1] The data includes both adult and younger patient groups, depending on the cancer type and study plan.[1]
Cancer types studied
Vibostolimab was studied across a wide range of cancers.[1] These included melanoma, non-small cell lung cancer, small-cell lung cancer, bladder cancer, kidney cancer, colorectal cancer, and metastatic castration-resistant prostate cancer.[1]
Some studies focused on special subgroups, such as people with PD-L1 positive tumors, people with PD-1 refractory melanoma, and people with MSI-H or dMMR colorectal cancer.[1] One trial also included pediatric and young adult participants with hematologic malignancies or solid tumors, but that study was withdrawn.[1]
Trial phases and study designs
The studies covered several stages of clinical research, including Phase 1, Phase 2, Phase 3, and one Phase 4 study.[1] There was also one study described as low intervention, which means the study used treatments in a more limited or routine way compared with many research trials.[1]
Early-phase studies mainly looked at safety, side effects, and whether the treatment could be given in a practical way.[1] Later-phase studies compared Vibostolimab-containing treatment plans with other standard cancer treatments and measured how well they worked over time.[1]
Who could take part
Each trial had its own entry rules based on the cancer type and disease stage.[1] For example, some studies included people with metastatic disease, which means the cancer had spread to other parts of the body.[1]
Other studies focused on people whose tumors had certain markers, such as PD-L1 expression, or people whose cancer had already not responded to earlier treatment, such as PD-1 refractory melanoma.[1] In some studies, participants had newly diagnosed advanced cancer, while in others they had cancer that had returned, spread, or was resistant to prior therapy.[1]
Main outcomes measured
The trials measured several important outcomes, depending on the cancer type and study phase.[1] Common results included overall survival, progression-free survival, objective response rate, and recurrence-free survival.[1]
Some studies also measured complete response, pathological complete response, and PSA response in prostate cancer.[1] Safety outcomes were also important, including the number of participants with adverse events, dose-limiting toxicities, or treatment stopping because of side effects.[1]
Key studies in the data
Melanoma studies included several Phase 1 and Phase 3 trials. One completed Phase 1 study in stage IIIB, IIIC, or IIID melanoma measured adverse events, treatment stopping due to adverse events, and pathological complete response.[1] Another Phase 1 study in PD-1 refractory melanoma looked at safety, tolerability, and objective response rate.[1] A Phase 3 study in high-risk resected melanoma was withdrawn and planned to compare recurrence-free survival.[1]
Lung cancer studies formed a major part of the dataset. A Phase 2 study in non-small cell lung cancer looked at progression-free survival with Vibostolimab-containing treatment compared with docetaxel alone.[1] Two Phase 3 studies in metastatic or stage IV non-small-cell lung cancer measured overall survival in PD-L1 positive groups.[1] Another authorised Phase 3 study in extensive-stage small-cell lung cancer compared overall survival between Vibostolimab-containing treatment and atezolizumab-based treatment.[1]
Bladder and kidney cancer studies also tested Vibostolimab-containing regimens. A Phase 2 study in non-muscle invasive bladder cancer measured complete response and 12-month disease-free survival.[1] A Phase 1 kidney cancer study measured safety in a lead-in part and objective response rate in the efficacy part.[1]
Other studies included metastatic castration-resistant prostate cancer, MSI-H or dMMR stage IV colorectal cancer, and pediatric or young adult cancers.[1] These trials mainly focused on safety and response, and some were authorised while others were completed or withdrawn.[1]
What these trials mean for patients
For patients, these studies show that Vibostolimab was mainly explored as part of combination treatment for difficult cancers.[1] The trials were designed to find out whether the treatment could help shrink cancer, delay growth, prevent recurrence, or improve survival.[1]
The data also shows that researchers paid close attention to safety, especially in early-phase studies and in groups with advanced disease.[1] Because the studies used different cancer types and different endpoints, the results cannot be treated as one single answer for all patients.[1]
